Physician profile
Melissa Vickers
NPI 1225256225
$8,739.62
in general payments reported to CMS, 2019-2025
19 companies · $1,450 in 2025
The $1,450 reported for 2025 was more than what 87% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,070 · 2022: $1,662 · 2023: $2,043 · 2024: $1,516 · 2025: $1,450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,847 · Education: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,847.04 |
| Education | $161.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,718.03 | 2021-2025 | Caplyta |
| Abbvie INC. | $1,491.00 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $911.14 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $888.32 | 2021-2025 | Uzedy, Austedo Xr, Austedo |
| Alkermes, INC. | $834.28 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $694.61 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $534.51 | 2021-2025 | Invega Sustenna, Spravato, Invega |
| Indivior INC. | $368.79 | 2021-2024 | Perseris |
| Lundbeck LLC | $367.61 | 2021-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $256.88 | 2021-2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $226.32 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $220.91 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $91.44 | 2021-2025 | Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.17 | 2022-2025 | Xifaxan |
| Janssen Biotech, INC. | $23.23 | 2025 | Tremfya |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.41 | 2025 | Abilify Maintena |
| Almatica Pharma LLC | $16.99 | 2025 | Loreev Xr |
| Allergan, INC. | $14.98 | 2021 | |
| Noven Therapeutics, LLC | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Vickers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.